Merck + Co., Inc.

Pfizer Corporation

Merial Limited

Merck Sharp + Dohme Corp.

Paul A Liberator

Scott D Feighner

Helen Profous-Juchelka

Kathrin Ute Jansen

Annaliesa Sybil Anderson

Alex Elbrecht

Michael Dashkevicz

Prasanta R Chakraborty

Lakshmi Khandke

Thomas Richard Jones

John Lance Perez

Shannon Lea Harris

Judith Absalon

Johannes Frederik Beeslaar

Gary Warren Zlotnick

Leah Diane Fletcher

John Erwin Farley

Dennis M Schmatz

David Cooper

Anne M Gurnett

Lynn Marie Phelan

Jose Miguel Aste-Amezaga

Isis Kanevsky

Robert G K Donald

Georgianna S Harris

Sandra J Rattray

Robert Donald

Mark Edward Ruppen

Jianxin Gu

Avvari Krishna Prasad

Jin-Hwan Kim

Rajesh Kumar Kainthan

Amardeep Singh Bhupender Bhalla

Ingrid Lea Scully

Cindy Xudong Yang

Suddham Singh

Leonardus H T Van Der Ploeg

Andrew D Howard

Doris F Cully

Joseph P Arena

Mervyn J Turner

James M Schaeffer

Jason Douglas Maguire

Cuiwen Tan

Xiaotian Zhong

Carmen Diaz

In one aspect, the disclosure relates to a composition including a factor H binding protein (fHBP) and anon-serogroup B capsular polysaccharide, and methods of use thereof. The disclosure further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response againstserogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

Neisseria meningitidis compositions and methods thereof

In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and anon-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response againstserogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

compositions and methods thereof

The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from, commonly referred to as group B(GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Group Bpolysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof

[object Object]

Protozoal cyclic GMP dependent protein kinases have been isolated and cloned. These enzymes may be used in screening assays to identify potential antiprotozoal agents.

Toxoplasma gondii cylclic GMP dependent protein kinase G as a chemotherapeutic target for antiprotozoal agents

Isolated nucleic acid molecules encoding coccidian casein kinase I, CKI, enzymes from the speciesandare disclosed. The isolation of these coccidian CKI cDNA sequences results in the disclosure of purified forms ofandCKI proteins, recombinant vectors and recombinant hosts which express coccidian CKI.

Polynucleotides encoding coccidian parasite casein kinase I, a chemotherapeutic target for antiprotozoal agents

The present invention relates to novel protozoal cyclic GMP dependent protein kinases and genes encoding same that have been isolated fromand. Nucleic acid molecules having sequences that encode such proteins as well as antibodies raised against such proteins are also disclosed. These enzymes may be used in screening assays to identify potential antiprotozoal agents. As well, methods to obtain such nucleic acid molecules, proteins, antibodies and inhibitor are also provided as are therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies and inhibitors as well as their use to protect animals from disease caused by parasites such asand

Cyclic GMP dependent protein kinase as a chemotherapeutic target for antiprotozoal agents

Polynucleotide encoding eimeria tenella cGMP dependent protein kinase

Human, swine and rat growth hormone secretagogue receptors have been isolated, cloned and sequenced. Growth hormone secretagogue receptors are new members of the G-protein family of receptors. The growth hormone secretagogue receptors may be used to screen and identify compounds which bind to the growth hormone secretagogue receptor. Such compounds may be used in the treatment of conditions which occur when there is a shortage of growth hormone, such as observed in growth hormone deficient children, elderly patients with musculoskeletal impairment and recovering from hip fracture and osteoporosis.

Growth hormone secretagogue receptor family

Genes coding for novel Group B Eimeria tenella protein immunogens have been isolated and inserted into a novel expression vector which in turn has been used to transform appropriate hosts. The transformed host cells produce recombinant Group B E. tenella proteins which are capable of inducing immunity in chickens to coccidiosis.

Recombinant and native group B eimeria tenella immunogens useful as

Unique species-specific Eimeria tenella DNA probes comprising divergent DNA sequences are disclosed. The probes are complementary to a small subunit ribosomal RNA gene of Eimeria tenella.

Eimeria tenella 16S rDNA probes

Growing community of inventors

Jackson, NJ, United States of America

Paul A Liberator